{Reference Type}: Journal Article
{Title}: DMPK perspective on quantitative model analysis for chimeric antigen receptor cell therapy: Advances and challenges.
{Author}: Goto A;Moriya Y;Nakayama M;Iwasaki S;Yamamoto S;
{Journal}: Drug Metab Pharmacokinet
{Volume}: 56
{Issue}: 0
{Year}: 2024 Jun 14
{Factor}: 2.041
{DOI}: 10.1016/j.dmpk.2024.101003
{Abstract}: Chimeric antigen receptor (CAR) cells are genetically engineered immune cells that specifically target tumor-associated antigens and have revolutionized cancer treatment, particularly in hematological malignancies, with ongoing investigations into their potential applications in solid tumors. This review provides a comprehensive overview of the current status and challenges in drug metabolism and pharmacokinetics (DMPK) for CAR cell therapy, specifically emphasizing on quantitative modeling and simulation (M&S). Furthermore, the recent advances in quantitative model analysis have been reviewed, ranging from clinical data characterization to mechanism-based modeling that connects in vitro and in vivo nonclinical and clinical study data. Additionally, the future perspectives and areas for improvement in CAR cell therapy translation have been reviewed. This includes using formulation quality considerations, characterization of appropriate animal models, refinement of in vitro models for bottom-up approaches, and enhancement of quantitative bioanalytical methodology. Addressing these challenges within a DMPK framework is pivotal in facilitating the translation of CAR cell therapy, ultimately enhancing the patients' lives through efficient CAR cell therapies.